View in EDS

Machine learning estimated probability of relapse in early-stage non-small-cell lung cancer patients with aneuploidy imputation scores and knowledge graph embeddings.

Saved in:
Bibliographic Details
Title: Machine learning estimated probability of relapse in early-stage non-small-cell lung cancer patients with aneuploidy imputation scores and knowledge graph embeddings.
Authors: Buosi, Samuele1 (AUTHOR) samuele.buosi@universityofgalway.ie, Timilsina, Mohan1 (AUTHOR) mohan.timilsina@universityofgalway.ie, Janik, Adrianna2 (AUTHOR) adrianna.janik@accenture.com, Costabello, Luca2 (AUTHOR) luca.costabello@accenture.com, Torrente, Maria3 (AUTHOR) maria.torrente@salud.madrid.org, Provencio, Mariano3 (AUTHOR) mariano.provencio@salud.madrid.org, Fey, Dirk4 (AUTHOR) dirk.fey@ucd.ie, Nováček, Vít1,5,6 (AUTHOR) vit.novacek@insight-centre.org
Source: Expert Systems with Applications. Jan2024, Vol. 235, pN.PAG-N.PAG. 1p.
Subjects: Non-small-cell lung carcinoma, Knowledge graphs, Multiple imputation (Statistics), Machine learning, Cancer patients, Aneuploidy, Lung cancer, Machine theory, Missing data (Statistics)
Abstract: Low-stage lung cancer is known to recur unpredictably, and patients receiving various treatment methods like radiation, chemotherapy, and immunotherapies have been seen to respond very differently. Identifying a priori if a patient is going to relapse or not could make a difference in terms of saving lives and personalized care offered. In this work, we provide an answer to the following research question: Is it possible to enhance the machine learning (ML) of the estimated probability of relapse in early-stage non-small-cell lung cancer (NSCLC) patients with aneuploidy imputation scores? To predict recurrence in 1,348 early-stage (I–II) NSCLC patients, we train graph ML models utilizing the Spanish pulmonary cancer group knowledge graph enriched with triples from pathway imputation. ML models trained on Knowledge graph data enriched with triples from pathway score imputation present an 82% Precision and 91% Specificity in predicting relapse over 200 patients from a held-out test set. ML models trained using graphs data could prove useful supplemental tool in the TNM classification systems and improve a lung cancer patient's prognosis. [ABSTRACT FROM AUTHOR]
Copyright of Expert Systems with Applications is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Low-stage lung cancer is known to recur unpredictably, and patients receiving various treatment methods like radiation, chemotherapy, and immunotherapies have been seen to respond very differently. Identifying a priori if a patient is going to relapse or not could make a difference in terms of saving lives and personalized care offered. In this work, we provide an answer to the following research question: Is it possible to enhance the machine learning (ML) of the estimated probability of relapse in early-stage non-small-cell lung cancer (NSCLC) patients with aneuploidy imputation scores? To predict recurrence in 1,348 early-stage (I–II) NSCLC patients, we train graph ML models utilizing the Spanish pulmonary cancer group knowledge graph enriched with triples from pathway imputation. ML models trained on Knowledge graph data enriched with triples from pathway score imputation present an 82% Precision and 91% Specificity in predicting relapse over 200 patients from a held-out test set. ML models trained using graphs data could prove useful supplemental tool in the TNM classification systems and improve a lung cancer patient's prognosis. [ABSTRACT FROM AUTHOR]
ISSN:09574174
DOI:10.1016/j.eswa.2023.121127